Phathom Pharmaceuticals Inc [NASDAQ: PHAT] closed the trading session at $9.52.
The stocks have a year to date performance of 4.27 percent and weekly performance of -48.18 percent. The stock has been moved at -8.37 percent over the last six months. The stock has performed -37.70 percent around the most recent 30 days and changed -23.47 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 1.07M shares, PHAT reached to a volume of 10371882 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Phathom Pharmaceuticals Inc [PHAT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PHAT shares is $25.29 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PHAT stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Phathom Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 03, 2024. While these analysts kept the previous recommendation, Needham raised their target price from $23 to $26. The new note on the price target was released on January 05, 2024, representing the official price target for Phathom Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $28, while H.C. Wainwright analysts kept a Buy rating on PHAT stock.
The Average True Range (ATR) for Phathom Pharmaceuticals Inc is set at 1.72, with the Price to Sales ratio for PHAT stock in the period of the last 12 months amounting to 24.78.
PHAT stock trade performance evaluation
Phathom Pharmaceuticals Inc [PHAT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -48.18. With this latest performance, PHAT shares dropped by -37.70% in over the last four-week period, additionally sinking by -8.37% over the last 6 months – not to mention a rise of 26.76% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PHAT stock in for the last two-week period is set at 24.33, with the RSI for the last a single of trading hit 17.80, and the three-weeks RSI is set at 29.58 for Phathom Pharmaceuticals Inc [PHAT]. The present Moving Average for the last 50 days of trading for this stock 17.08, while it was recorded at 15.20 for the last single week of trading, and 12.11 for the last 200 days.
Phathom Pharmaceuticals Inc [PHAT]: An insightful look at the core fundamentals
Phathom Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.68 and a Current Ratio set at 5.73.
Phathom Pharmaceuticals Inc [PHAT]: Institutional Ownership
There are presently around $92.99%, or 100.74%% of PHAT stock, in the hands of institutional investors. The top three institutional holders of PHAT stocks are: FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with ownership of 10.11 million shares, which is approximately 17.3189%. MEDICXI VENTURES MANAGEMENT (JERSEY) LTD, holding 7.46 million shares of the stock with an approximate value of $$76.89 million in PHAT stocks shares; and MEDICXI VENTURES MANAGEMENT (JERSEY) LTD, currently with $$35.84 million in PHAT stock with ownership which is approximately 5.9906%.
